<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Tapson, Victor F.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">VTE: Treatment, Prevention of Recurrence, Thrombolysis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">24-25</style></pages><abstract><style  face="normal" font="default" size="100%">Venous thromboembolism (VTE) is a common problem, at a prevalence of 1 to 2 VTEs per 1000 patients, with an in-hospital fatality rate of up to 12%. This article discusses novel oral anticoagulants that have become available for treatment over the past 5 years, the prevention of recurrent VTE, and thrombolytic therapy for the treatment of acute pulmonary embolism.</style></abstract><number><style face="normal" font="default" size="100%">45</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>